Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 65 articles:
HTML format
Text format



Single Articles


    June 2018
  1. WANG K, Ji W, Yu Y, Li Z, et al
    FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0311.
    PubMed     Text format     Abstract available


    May 2018
  2. JI X, Qian J, Rahman SMJ, Siska PJ, et al
    xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0307.
    PubMed     Text format     Abstract available


  3. ZHAO C, Li Y, Qiu W, He F, et al
    C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0298.
    PubMed     Text format     Abstract available


    April 2018
  4. WANG S, Jia M, He Z, Liu XS, et al
    APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0245.
    PubMed     Text format     Abstract available


  5. TOMOSHIGE K, Guo M, Tsuchiya T, Fukazawa T, et al
    An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Oncogene. 2018 Apr 17. pii: 10.1038/s41388-018-0240.
    PubMed     Text format     Abstract available


  6. NEWMAN JH, Augeri DJ, NeMoyer R, Malhotra J, et al
    Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
    Oncogene. 2018 Apr 6. pii: 10.1038/s41388-018-0156.
    PubMed     Text format     Abstract available


  7. PENTIMALLI F, Forte IM, Esposito L, Indovina P, et al
    RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
    Oncogene. 2018 Apr 2. pii: 10.1038/s41388-018-0214.
    PubMed     Text format     Abstract available


    March 2018
  8. MONTERISI S, Riso PL, Russo K, Bertalot G, et al
    HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.
    Oncogene. 2018 Mar 26. pii: 10.1038/s41388-018-0229.
    PubMed     Text format     Abstract available


  9. MEDER L, Konig K, Dietlein F, Macheleidt I, et al
    LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model.
    Oncogene. 2018 Mar 5. pii: 10.1038/s41388-018-0158.
    PubMed     Text format     Abstract available


    February 2018
  10. LAI Q, Wang H, Li A, Xu Y, et al
    Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Oncogene. 2018 Feb 9. pii: 10.1038/s41388-018-0125.
    PubMed     Text format     Abstract available


    January 2018
  11. WELCKER D, Jain M, Khurshid S, Jokic M, et al
    AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0054.
    PubMed     Text format     Abstract available


    November 2017
  12. SZYMICZEK A, Carbone M, Pastorino S, Napolitano A, et al
    Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
    Oncogene. 2017;36:6501-6507.
    PubMed     Text format     Abstract available


  13. ZHONG Y, Yang J, Xu WW, Wang Y, et al
    KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
    Oncogene. 2017;36:6177-6189.
    PubMed     Text format     Abstract available


  14. TORRENTE L, Sanchez C, Moreno R, Chowdhry S, et al
    Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.
    Oncogene. 2017;36:6204-6212.
    PubMed     Text format     Abstract available


  15. TRINIDAD AG, Whalley N, Rowlinson R, Delpuech O, et al
    Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
    Oncogene. 2017;36:6164-6176.
    PubMed     Text format     Abstract available


    October 2017
  16. REN T, Zhang H, Wang J, Zhu J, et al
    MCU-dependent mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells.
    Oncogene. 2017;36:5897-5909.
    PubMed     Text format     Abstract available


  17. IVANOV AA, Gonzalez-Pecchi V, Khuri LF, Niu Q, et al
    OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc.
    Oncogene. 2017;36:5852-5860.
    PubMed     Text format     Abstract available


  18. SPOLVERINI A, Fuchs G, Bublik DR, Oren M, et al
    let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery.
    Oncogene. 2017;36:5819-5828.
    PubMed     Text format     Abstract available


  19. CHHABRA Y, Wong HY, Nikolajsen LF, Steinocher H, et al
    A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  20. KATO T, Sato T, Yokoi K, Sekido Y, et al
    E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
    Oncogene. 2017;36:5522-5531.
    PubMed     Text format     Abstract available


  21. ZHANG Y, Hu Y, Wang JL, Yao H, et al
    Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp.
    Oncogene. 2017;36:5473-5483.
    PubMed     Text format     Abstract available


  22. KIM M, Jang K, Miller P, Picon-Ruiz M, et al
    VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
    Oncogene. 2017;36:5199-5211.
    PubMed     Text format     Abstract available


  23. CHEN G, Zhang B, Xu H, Sun Y, et al
    Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  24. YAN F, Shen N, Pang J, Zhao N, et al
    A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    August 2017
  25. YURUGI H, Marini F, Weber C, David K, et al
    Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Oncogene. 2017;36:4778-4789.
    PubMed     Text format     Abstract available


    July 2017
  26. VELMURUGAN KR, Varghese RT, Fonville NC, Garner HR, et al
    High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  27. GARNETT S, Dutchak KL, McDonough RV, Dankort D, et al
    p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  28. UMEDA Y, Hasegawa Y, Otsuka M, Ariki S, et al
    Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  29. WU DW, Lee MC, Hsu NY, Wu TC, et al
    FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappaB/Slug-mediated PUMA reduction.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  30. WANG J, Jia Y, Zhao S, Zhang X, et al
    BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  31. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  32. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  33. FENG J, Yang H, Zhang Y, Wei H, et al
    Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  34. SZCZEPNY A, Rogers S, Jayasekara WSN, Park K, et al
    The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  35. LIAO SY, Chiang CW, Hsu CH, Chen YT, et al
    CK1delta/GSK3beta/FBXW7alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  36. LI H, Xiao N, Wang Y, Wang R, et al
    Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIgamma.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  37. WANG Q, Ma J, Lu Y, Zhang S, et al
    CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
    Oncogene. 2017 May 22. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  38. CHOI EJ, Jung BJ, Lee SH, Yoo HS, et al
    A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  39. HSU YL, Hung JY, Chang WA, Lin YS, et al
    Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  40. AMBROGIO C, Barbacid M, Santamaria D
    In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Oncogene. 2017;36:2309-2318.
    PubMed     Text format     Abstract available


  41. LU W, Cheng F, Yan W, Li X, et al
    Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  42. OHM AM, Tan AC, Heasley LE, Reyland ME, et al
    Co-dependency of PKCdelta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  43. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format    


  44. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  45. SHAKYA R, Tarulli GA, Sheng L, Lokman NA, et al
    Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  46. BOUILLEZ A, Rajabi H, Jin C, Samur M, et al
    MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  47. SHI ZM, Wang L, Shen H, Jiang CF, et al
    Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.
    Oncogene. 2017 Feb 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  48. HSIEH CH, Chou YT, Kuo MH, Tsai HP, et al
    A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  49. ENDO H, Okami J, Okuyama H, Nishizawa Y, et al
    The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  50. SHI L, Wang Y, Lu Z, Zhang H, et al
    miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  51. GUO JY, Hsu HS, Tyan SW, Li FY, et al
    Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  52. CHEN F, Zhang Y, Parra E, Rodriguez J, et al
    Multiplatform-based molecular subtypes of non-small-cell lung cancer.
    Oncogene. 2016 Oct 24. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  53. WANG D, Shi W, Tang Y, Liu Y, et al
    Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  54. PENG DH, Ungewiss C, Tong P, Byers LA, et al
    ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    August 2016
  55. ZELENKO Z, Gallagher EJ, Tobin-Hess A, Belardi V, et al
    Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression.
    Oncogene. 2016 Aug 29. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  56. KAO YC, Jheng JR, Pan HJ, Liao WY, et al
    Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling.
    Oncogene. 2016 Aug 8. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  57. CHIU LY, Hsin IL, Yang TY, Sung WW, et al
    The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  58. MA Y, Yu C, Mohamed EM, Shao H, et al
    A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
    Oncogene. 2016 May 2. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    April 2016
  59. DODD RD, Sachdeva M, Mito JK, Eward WC, et al
    Myogenic transcription factors regulate pro-metastatic miR-182.
    Oncogene. 2016;35:1868-75.
    PubMed     Text format     Abstract available


    January 2016
  60. LAKSHMANAN I, Rachagani S, Hauke R, Krishn SR, et al
    MUC5AC interactions with integrin beta4 enhances the migration of lung cancer cells through FAK signaling.
    Oncogene. 2016 Jan 11. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    November 2015
  61. WANG YC, Wang SA, Chen PH, Hsu TI, et al
    Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.
    Oncogene. 2015 Nov 16. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  62. MALIN D, Strekalova E, Petrovic V, Rajanala H, et al
    ERK-regulated alphaB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.
    Oncogene. 2015;34:5626-34.
    PubMed     Text format     Abstract available


    October 2015
  63. KAUR J, Tikoo K
    Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation.
    Oncogene. 2015;34:5216-28.
    PubMed     Text format     Abstract available


    June 2015
  64. CASTILLO-LLUVA S, Hontecillas-Prieto L, Blanco-Gomez A, Del Mar Saez-Freire M, et al
    A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development.
    Oncogene. 2015 Jun 22. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    January 2015
  65. FAN LC, Shiau CW, Tai WT, Hung MH, et al
    SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
    Oncogene. 2015 Jan 26. doi: 10.1038/onc.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: